Symbio Pharmaceuticals Limited

As of June 30, 2026, Symbio Pharmaceuticals Limited carries a market capitalization of 5.27B, placing it among publicly traded companies globally. Its enterprise value stands at 5.12B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Symbio Pharmaceuticals Limited's next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Symbio Pharmaceuticals Limited has 76.34M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Symbio Pharmaceuticals Limited maintains a current ratio of 0.75, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Symbio Pharmaceuticals Limited recorded 15.80M in income tax expense.

As of the close on October 22, 2026, Symbio Pharmaceuticals Limited's stock has declined approximately 61.90% over the past 52 weeks. The 50-day moving average sits at 59.24, while the 200-day moving average is 83.69.

As of June 30, 2026, Symbio Pharmaceuticals Limited holds 977.18M in cash and equivalents against 832.50M in total debt, resulting in a net debt position of -144.68M. Total book value stands at -582.85M, with working capital of -619.52M providing operational flexibility.

Symbio Pharmaceuticals Limited's most recent stock split took place on June 26, 2019 with a 4:1 split ratio.